DiaCarta Growth, Revenue, Number of Employees and Funding

Overview

Location:
Total Funding:$53M
Industry:Biotech
Founded:2010
Lead Investor(s):Fortune Fountain Capital
Press

Estimated Revenue & Financials

  • DiaCarta's estimated revenue is currently $6.2M per year.
  • DiaCarta received $45.0M in venture funding in February 2018.
  • DiaCarta's estimated revenue per employee is $144186
  • DiaCarta's total funding is $53M.

Employee Data

  • DiaCarta has 43 Employees.
  • DiaCarta grew their employee count by 10% last year.
  • DiaCarta currently has 1 job openings.

Executive Contacts

NameTitle
Elena PeletskayaDirector, Molecular Analytics, Juno Therapeutics
Aiguo ZhangFounder, President & CEO
Michael PowellChief Scientific Officer
Nitin UdarSr VP Diagnostics and Regulatory
Robyn SchlicherSenior Director of Sales
Ke ZhanDirector, NGS

What Is DiaCarta?

DiaCarta is a translational genomics and personalized diagnostics company that provides ultra-sensitive detection tools for cancer diagnosis, therapy identification and prognosis monitoring. Our mission is to provide ultra-sensitive and advanced technologies that will redefine the way molecular diagnostics and translational genomics impact healthcare treatment plans and the well-being of individuals around the world. To learn more, visit http://www.diacarta.com.

keywords:Biotechnology,Healthcare,Medical Diagnostics,Pharmaceuticals

43

Number of Employees

$6.2M

Revenue (est)

1

Current Jobs

10%

Employee Growth %

$53M

Total Funding

N/A

Valuation

N/A

Accelerator

B2B

Type

Similar Companies

NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
DiaCarta
$6.2M4310%N/A
Mission Bio
$10.7M7445%N/A
Rigel Pharmaceu...
$42M2904%N/A
ProTrials Resea...
$26.4M1823%N/A
Trace Genomics
$5.9M4137%N/A
Advanced Cell D...
$25.7M1788%N/A
CellMax Life
$5.7M4011%N/A
Vaxart
$4.2M33-15%N/A
Full Spectrum A...
$6M425%N/A
Calysta
$7.1M49-2%N/A

DiaCarta News

10/15/2018 - DiaCarta, Inc., Awarded $2 Million NCI Contract to Pursue ...

BUSINESS WIRE)--DIACARTA, Inc., a precision diagnostic company and leading developer of products for nucleic acid-based detection ...

01/17/2019 - CIO Bulletin Announces DiaCarta Inc. As One of the 30 ...

RICHMOND, Calif.--(BUSINESS WIRE)--DiaCarta today announced that CIO Bulletin has named it among the 30 Fastest Growing Companies ...

02/12/2018 - DiaCarta Raises $45M in Series B Funding

NEW YORK (GenomeWeb) – DiaCarta said today that it has completed a Series B funding round, raising a total of $45 million. The second ...

DiaCarta Funding

DateAmountRoundLead InvestorsReference
2015-01-12$8.0MABVCFArticle
2018-02-13$45.0MBFortune Fountain CapitalArticle